MHRA Field Safety Notices 1-5 June 2026: Device Recalls Impact UK Healthcare Supply Chains
The MHRA has published Field Safety Notices (FSNs) for the first week of June 2026, detailing multiple medical device recalls affecting UK healthcare providers. Brand owners and procurement leads must assess their supply chain exposure and implement critical-device contingency plans.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 08 June 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued its weekly compilation of Field Safety Notices (FSNs) for 1-5 June 2026, flagging several medical devices requiring immediate attention from manufacturers and healthcare providers. While the MHRA clarifies these FSNs are for informational purposes, the responsibility for action rests with the entities receiving them. This alert system is critical for maintaining patient safety and ensuring the integrity of the UK’s medical device supply chain.
Key devices subject to FSNs include specific models from Berchtold (CHROMOPHARE), Bolton Medical (RelayPro Thoracic Stent-Graft System), EKF-diagnostic (Chip Sensor Lactate), ELLA-CS (SX-ELLA Stent Danis), and Fresenius (Sleep Safe Harmony). Additionally, Ivor Shaw Limited (t/a Pennine Healthcare) for B.Braun Procedure Packs, Löwenstein (LEONI 4, elisa series), Medtronic (DLP One-Piece Pediatric Arterial Cannulae, Harmony), PolyNovo Biomaterials (NovoSorb BTM), and Stryker (INZONE DETACHMENT SYSTEM) are also impacted. These notices typically detail product defects, performance issues, or labelling inaccuracies that necessitate corrective actions such as recalls, modifications, or revised usage instructions.
For manufacturers, receiving an FSN triggers mandatory recall procedures, which involve direct communication with affected customers, coordination of product retrieval, and often, root cause analysis to prevent future recurrence. The financial implications can be significant, encompassing not only direct recall costs but also reputational damage and potential market share erosion. For UK brand owners, understanding the scope and implications of these FSNs is paramount to ensure compliance and minimise disruption.
What this means for United Kingdom
UK manufacturers cited in these FSNs must initiate their recall protocols immediately, aiming for full compliance and MHRA reporting by 19 June 2026. This includes notifying all distributors and end-users, retrieving affected stock, and implementing corrective and preventive actions. Brand owners sourcing components or finished goods from these manufacturers must audit their inventory for impacted batches and activate contingency plans, potentially facing 15-20% higher procurement costs for replacement stock or extended lead times of 4-6 weeks. Procurement leads in NHS trusts and private clinics must urgently cross-reference their current stock against the FSN list, quarantining affected devices and securing verified alternatives to prevent service interruptions, especially for critical care or surgical instruments. Failure to act swiftly risks patient safety incidents and significant regulatory penalties from the MHRA.
The MHRA continues to stress that while they publish these notices, the onus is on the manufacturer to directly inform affected parties and ensure corrective measures are implemented. Procurement teams within healthcare organisations must implement robust tracking systems for FSNs and maintain direct communication channels with their suppliers. The ongoing vigilance required to monitor these notices underscores the stringent regulatory environment governing medical devices in the UK.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.